DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/fqs7nv/pocket_handbook_of) has announced the addition of the "Pocket Handbook of Small Animal Medicine" book to their offering.

Concise, problem-oriented and accessibly designed, the Pocket Handbook focuses throughout on the essentials of medicine and surgery of the dog and cat. The book's aim is to help start the process of case management and resolution. There are tips and hints on interpretation of physical signs, diagnostic tests and management of common presenting conditions. Algorithms used to assist decision-making are a major feature of the book. They are used extensively in part 2 Clinical presentations' and in Part 5 Critical care'. Commonly used drugs, their dose rates and precautions are presented in tabular form. Colour diagrams and photos illustrate key points.

The Pocket Handbook is an indispensable rapid reference guide and revision aid for veterinary students, recently-qualified practitioners and those returning to small animal practice.

KEY FEATURES

- Author a clinician with 25 years' of first opinion and referral practice experience

- Focus on essentials of medicine and surgery

- Concise, well-illustrated, low cost

- Rapid reference & revision aid

Key Topics Covered:

Follow this link:

Research and Markets: Pocket Handbook of Small Animal Medicine

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/36w3mw/small_animal_cardi) has announced the addition of the "Small Animal Cardiopulmonary Medicine - Self-Assessment Color Review" book to their offering.

SELF-ASSESSMENT COLOUR REVIEWS IN VETERINARY MEDICINE: Each book covers a specialist area of veterinary medicine and the format enables the reader to consider a problem fully and then devise a solution.

Dr Wendy Ware, author of the highly acclaimed Cardiovascular Disease in Small Animal Medicine, has brought together specialist contributors to produce this important addition to the Self-Assessment Color Review series.

The book presents a wide variety of cases involving cardiothoracic diseases, mainly focusing on the causes of respiratory distress and other clinical signs that relate to lower respiratory, cardiac or other intrathoracic disorders. Many cases in the book involve common diseases and focus on diagnosis and management, but some more unusual and challenging cases are also featured. The 218 cases comprising questions, illustrations and detailed explanatory answers appear randomly to reflect real life practice, and are designed not only to test the ability of the reader but also to educate and inform.

This Self-Assessment Color Review is of value to all veterinary practitioners with an interest in canine and feline cardiothoracic diseases who wish to reinforce their clinical skills, to those veterinarians and veterinary nurses/technicians preparing for higher qualifications and to veterinary students as an aid to learning and revision.

KEY FEATURES

- Systematic coverage in randomised order

- Thought provoking self-assessment format

- Superb illustrations and detailed explanatory answers

Read the original post:

Research and Markets: Small Animal Cardiopulmonary Medicine - Self-Assessment Color Review

HOLLYWOOD, Calif., May 4, 2012 /PRNewswire/ -- Medicine Dispensing Systems, Inc., a subsidiary of Medbox, Inc. (MDBX.PK) (www.medboxinc.com) is preparing to assist companies and individuals open legal and fully compliant medical marijuana clinics in the state of Connecticut.

The Connecticut House of Representatives voted 96-51 this April to legalize the plant for adults with a prescription from a physician to relieve pain from various illnesses and ailments such as cancer, glaucoma, HIV and multiple sclerosis.

Under the provisions of the new legislation, licensed pharmacists could provide the marijuana to patients who have a physician's prescription. Patients would need to requalify every year. The bill also prevents all prison inmates and anyone younger than 18 from obtaining medical marijuana to relieve their pain, regardless of the extent of their illness.

Medicine Dispensing Systems is a leader in the medical marijuana industry, and provides unique and patented technology-based solutions that have gained acceptance in every state where the product is now legal. The company is considered the gold standard of how medical marijuana can be handled legally, transparently, and in full compliance of all state and local laws and regulations.

Medical marijuana eases pain and suffering for thousands of patients, and when properly prescribed and dispensed, creates a better quality of life for people with painful chronic conditions and debilitating disease.

The bill still has a few hurdles before passed into law, but it has wide spread support. Connecticut Representative Christopher Lyddy, a Newtown Democrat, said he supported the bill because of how devastating illness touched his own family.

"My father wanted just enough energy and comfort to hold his three new grandchildren,'' Lyddy told his colleagues. Lyddy's father passed away in 2006 from colon cancer.

The bill now moves to the Senate for further action.

About Medbox, Inc.:

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Tokyo and Toronto, and has their corporate headquarters in Los Angeles.

Follow this link:

Medicine Dispensing Systems Prepares to Help Operators Run Medical Marijuana Clinics in Full Compliance with ...

PHILADELPHIA Two Philadelphia-area residents have been named the winners of Penn Medicine's MyHeartMap Challenge, the citywide crowdsourcing contest aimed at locating and mapping all of the lifesaving automated external defibrillators in Philadelphia. Following a race the Challenge's directors described as "too close to call," Jennifer Yuan, an IT communications analyst, and Jack Creighton, an athletic director at Frankford High School, will each be awarded $9,000. Each winning competitor located more than 400 AEDs during the eight-week contest in February and March.

More than 300 individuals and teams participated in the Challenge. Together, they found, photographed, and submitted information about more than 1,500 AEDs in more than 800 unique buildings throughout Philadelphia County. Each one of the AEDs found represents fresh chances to save lives from sudden cardiac arrest, which kills more than 300,000 Americans each year.

The MyHeartMap Challenge research team congratulates each of the contest participants, who served as incredible informants in the effort to create a smart phone app and AED map to help 911 operators and bystanders locate the devices to use along with CPR while waiting for EMS to arrive during cardiac arrests in public places.

"Finding AEDs during this contest was a very hard task many AEDs, we found, are in places people wouldn't think to look during an emergency," says MyHeartMap Challenge director Raina Merchant, MD, an assistant professor of Emergency Medicine in the Perelman School of Medicine. "We're so impressed with the creative ways people sought out devices and provided us with information that we'll now be able to ensure that these devices are in the right place to save lives."

Merchant and her colleagues are now at work analyzing the data submitted by contest participants, and they hope to soon publish the results of the nation's first effort using crowdsourcing to save lives.

Among their goals, both in Philadelphia and in other cities where future MyHeartMap Challenges will be held: To help business owners make the devices more visible and accessible many found were stashed away in basements or closets and push for consistency in where the devices can be found during the emergency, much as fire extinguishers are placed in standardized locations.

In addition to the Challenge's individual winners, three Philadelphia schools -- McCall Elementary, Frankford High School, and Douglas High School will be awarded an AED by the Children's Hospital of Philadelphia Youth Heart Watch for being the top three schools to find AEDs.

A special awards ceremony this summer will recognize all MyHeartMap Challenge awardees and businesses that were found to have exemplary practices in AED availability and staff training, and honor cardiac arrest survivors and bystanders who stepped in save them. Although the contest is over, contestants and other community members may continue submitting AEDs photos and locations at myheartmap.org to help the research team build the database and map.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

View post:

Two Winners Take Grand Prize in Penn Medicine's MyHeartMap Challenge

National Herbal Medicine Week is a chance for the public to find out more about this effective and safe form of medicine that has benefited patients for thousands of years.Jacksonville, FL and Bethesda, MD (PRWEB) May 02, 2012 The National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM®) and the American Association for Acupuncture and Oriental Medicine (AAAOM) are ...

Read more:

National Herbal Medicine Week Established to Celebrate the Safe and Effective Practice of Herbal Therapies for ...

MIAMI--(BUSINESS WIRE)--

The University of Miami Miller School of Medicines Interdisciplinary Stem Cell Institute (ISCI) today announced that it received a $10 million grant from The Starr Foundation, one of the largest private foundations in the United States. The grant will support ISCI in broadening its preclinical and clinical research on stem cells, and help accelerate its pipeline of translational research and programs for a wide range of debilitating conditions including cardiac disease, cancer, wound healing, stroke, glaucoma and chronic kidney and gastrointestinal diseases.

This is a momentous and transformative gift for the Interdisciplinary Stem Cell Institute, said Joshua M. Hare, M.D., F.A.C.C., F.A.H.A., Louis Lemberg Professor of Medicine at the University of Miami Miller School of Medicine and director of ISCI. We are so gratified that the level of science being conducted here was recognized by this very generous grant from The Starr Foundation. With this award, we join the ranks of the other major top-tier universities funded by The Starr Foundation. This support, along with our growing NIH funding, technology transfer, and other philanthropic efforts guarantees the stability of ISCI through the end of the decade, and will allow us to continue to push the boundaries of regenerative medicine with the goal of improving human health.

Stem cells and regenerative medicine are poised to transform the way we practice medicine, cure disease and treat injuries. To realize this potential, the University of Miami Miller School of Medicine is performing world-leading research at ISCI, said Pascal J. Goldschmidt, M.D., Senior Vice President for Medical Affairs and Dean of the Miller School of Medicine, and Chief Executive Officer of the University of Miami Health System. We are extremely proud of this recognition by The Starr Foundation that ISCI, and the Miller School of Medicine, are leading the way for stem cell and regenerative medicine breakthroughs.

Donna E. Shalala, President of the University of Miami, said the grant from the foundation will have long-reaching implications for future medicine. The team at ISCI is making new discoveries on a number of fronts and this substantial support from The Starr Foundation propels that work forward, both in the laboratory and in clinical trials.

For more on the grant, click here.

See original here:

University of Miami’s Interdisciplinary Stem Cell Institute Awarded $10 Million Grant from Starr Foundation

SAN DIEGO, CA--(Marketwire -05/03/12)- Regen BioPharma (Regen), Inc. a newly-formed subsidiary of Bio-Matrix Scientific Group, Inc. (BMSN.PK - News) (BMSN.PK - News), unveiled today its operational plan for its "Super-Incubator" stem cell company.

Month 1-2: Assembly of Team. Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization.

Month 1-4: In-licensing of Intellectual Property. The Company having already assessed over 20,000 issued patents and having compiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses on issued patents that have already passed preclinical studies but are not under clinical development.

Month 3-6: Interaction with Regulatory Agencies. Regen intends to develop data packages for each of the technologies and initiate interaction with Regulatory Agencies such as the FDA for initiation of trials.

Month 6-18: Clinical Implementation. Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy.

Month 18-24: Exit. It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.

"At present there exists a wealth of intellectual property that is 'collecting dust' in the corridors of Academia. Given the field of regenerative medicine and stem cell therapy is so young, and the business models are fuzzy at best in terms of valuation, we see this space as a unique opportunity for acceleration of clinical development/value optimization," said Bio-Matrix Chairman & CEO David Koos about its Regen BioPharma. "Valuations for stem cell companies that have passed the threshold of clinical safety, with signals of efficacy are astronomical. The $1.8 billion Mesoblast-Cephalon deal, as well as recent financings of private companies with as little as 3 patient data such as Promethera ($31 million) or Allocure with 16 patients ($23 million), is testimony to the extremely high valuations that are characteristic of this space."

About Bio-Matrix Scientific Group, Inc.:

Bio-Matrix Scientific Group, Inc. (BMSN.PK - News) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.

Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.

Read the rest here:

Bio-Matrix Subsidiary "First in Class" Approach to Stem Cell Medicine

LONDON (Reuters) - A highly stimulatory monetary stance is the "the best medicine" to help rebalance Britain's economy, Bank of England deputy governor Charles Bean said in an opinion piece in the Financial Times on Friday. Bean defended the bank's stimulatory policy stance, which has come under renewed criticism as Britain slid into its second recession since the financial crisis. "The present ...

The rest is here:

Stimulus best medicine for UK, says BoE's Bean - FT

The National Institutes of Health should stop funding most studies of complementary and alternative medicine because they are not based on sound science, one prominent researcher argues.

Here is the original post:

Studies of Alternative Medicine Not Worth the Money, Doc Says

BOSTON--(BUSINESS WIRE)--

The New England Journal of Medicine (NEJM) announces the release of a documentary film, now available on the NEJM 200th Anniversary website, in celebration of 200 years of continuous publication. Getting Better is a three-part, 45-minute documentary that explores the evolution of knowledge in medicine and some of the remarkable advances reported in NEJM, including the use of anesthesia in surgery, successful cancer therapies, and treatments for HIV/AIDS.

Weve made so many advances in the field of medicine over the last 200 years, and peoples lives have greatly improved as a result, says Dr. Jeffrey Drazen, editor-in-chief of the New England Journal of Medicine. As a journal, the New England Journal of Medicine has played a role as an observer and an informer, and this film is a reflection of what weve seen. As patients, we have all benefited.

NEJM was founded in 1812 when surgery was unsanitary and performed without anesthesia, cancer went undiagnosed, and there was no understanding of infectious disease.

The first part of the film, From Rough to Refined: The Rise of Surgery, takes the viewer from the first public demonstration of ether anesthesia in 1846 to a modern-day operating room, where Dr. Atul Gawande performs a thyroidectomy. A segment on leukemia, Targeting Cancer: The Story of Leukemia, covers Dr. Sidney Farbers first successes in the treatment of early childhood leukemia in 1948 through the development of the first targeted therapy in 2001, the beginning of personalized medicine. In The Plague of our Time: HIV/AIDS Epidemic, Drs. Tony Fauci and Paul Farmer recall the first cases of HIV/AIDS, how doctors came to understand and treat the disease, and how the epidemic has been part of a revolution in access to care and knowledge.

Each segment of the film traces the connection between research discoveries and current practice, telling the story through the voices of prominent experts, practicing clinicians, patients, and advocates. The documentary illustrates the importance of medical research in shaping clinical practice and patient care; and, how technological advances have changed the speed and trajectory of information sharing, transforming knowledge into action.

A Nancy Porter Production, the film was written and directed by Nancy Porter, an Emmy award-winning filmmaker who has made numerous documentaries for PBS including several for NOVA andAmerican Experience, and produced by Kathryn Dietz, who has produced films for Frontlineand American Experience.

About The New England Journal of Medicine

The New England Journal of Medicine (NEJM.org) is the worlds leading medical journal and website. In 2012, NEJM celebrates 200 years of advancing medical science, practice and patient care. Each week, NEJM publishes peer-reviewed research and clinical content for physicians, educators and the global medical community. The New England Journal of Medicine is owned and published by the Massachusetts Medical Society.

Photos/MultimediaGallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50261616&lang=en

Read this article:

The New England Journal of Medicine Releases Documentary Film, Getting Better: 200 Years of Medicine

09-03-2012 09:20 Mon. 3/26 1pm EST. Taylor Momsen responds to your comments on the "My Medicine" video. Did she answer your question? Watch and find out. "My Medicine" by the Pretty Reckless: World premiere Directed by Meiert Avis, Taylor Momsen, and Stefan Smith HIT ME LIKE A MAN EP on iTunes myISH: Subscribe NOW to myISH: HIT ME LIKE A MAN EP on iTunes 'THE MEDICINE TOUR' tour dates: Fri-Mar-09 Tucson, AZ Club Congress Sat-Mar-10 Phoenix, AZ Martini Ranch Sun-Mar-11 Santa Ana, CA Constellation Room Wed-Mar-14 Los Angeles, CA House Of Blues Thu-Mar-15 San Francisco, CA Bottom Of The Hill Fri-Mar-16 Portland, OR Hawthorne Theatre Sat-Mar-17 Seattle, WA El Corazon Sun-Mar-18 Vancouver, BC Rickshaw Theatre Tue-Mar-20 Calgary, AB The Den Thu-Mar-22 Edmonton, AB Starlite Theatre Fri-Mar-23 Saskatoon, SK Louis Pub Sat-Mar-24 Regina, SK Exchange Mon-Mar-26 Winnipeg, MB West End Cultural Centre Thu-Mar-29 Chicago, IL Bottom Lounge Fri-Mar-30 Cleveland, OH HOB Cambridge Sat-Mar-31 Columbus, OH Newport Music Hall Sun-Apr-01 Toledo, OH Frankies Tue-Apr-03 Pontiac, MI The Crofoot Wed-Apr-04 Toronto, ON Phoenix Concert Hall Fri-Apr-06 Quebec City, QC Le Cercle Sat-Apr-07 Montreal, QC Metropolis Club Sun-Apr-08 Burlington, VT Higher Ground Tue-Apr-10 Boston, MA Paradise Rock Club Thu-Apr-12 Philadelphia, PA TLA Fri-Apr-13 New York, NY Irving Plaza Sat-Apr-14 Poughkeepsie, NY The Loft Sun-Apr-15 Baltimore, MD Ottobar Tue-Apr-17 Richmond, VA ...

Follow this link:

The Pretty Reckless - My Medicine - Official Music Video - Video

16-03-2012 11:35 Music video by The Pretty Reckless performing My Medicine. (C) 2012 Interscope Records

Here is the original post:

The Pretty Reckless - My Medicine - Video

21-03-2012 11:31 Buy the album 'O, Devotion!' here: CD: Digital: Directed by Joseph Brett & Simon Taffe, End of the Road Films http

Continued here:

Liz Green - Bad Medicine (OFFICIAL VIDEO) - Video

DALLAS, TX--(Marketwire -04/23/12)- Airway Management (www.amisleep.com) has formed the Dental Institute of Sleep Medicine (http://amisleep.com/training) for the purpose of training dental practitioners in the use of TAP oral appliance therapy for sleep disordered breathing. Upcoming courses are sponsored by TAP, VirtuOx, and Patterson Dental.

"By 2020, 40 percent of the U.S. population will have some form of sleep disordered breathing. With the failure of CPAP as a long-term therapy for many patients, dentists will play the key role in the management of these disorders, including snoring and sleep apnea. Demand for treatment of snoring and sleep apnea has increased exponentially, yet the dentist is confronted with what seems to be a great barrier due to the medical nature of the condition. The truth is that treating these patients can be accomplished easily, appropriately and profitably in the dental office," says Dr. W. Keith Thornton, inventor of the TAP and TAP PAP adjustable oral appliances for sleep disordered breathing. "I am delighted to join with Dr. Paul McLornan and Dr. Steve Bender in developing courses that will make it both efficient and effective for dentists to provide TAP appliance therapy."

All courses are in an interactive workshop format with didactic presentations, hands-on exercises, and ample time for questions and answers. An introductory 1-day course, titled "Jump Start Your Practice," and an intermediate 1-day course titled "Clinical Mastery" are being held on successive days at multiple Patterson Dental branches around the United States. A 3-day "Advanced Comprehensive Therapy" course is being held monthly at Airway Management in Dallas, Texas.

"One of the exciting aspects of our training," says Dr. Thornton, "is learning how to use and interpret an overnight pulse oximeter. We have created VirtuOx Professional Edition, which is a web-based patient management system. Participants in the courses learn how to gather specific information and use necessary forms for patient evaluation, how to deliver and adjust a TAP oral appliance, and how to fit a morning repositioner (the AM aligner). On completion of the second day of training (the Clinical Mastery course), the participant receives TAP Certification. In Dallas, the Advanced Comprehensive training is limited to 10 participants per session. It covers the curriculum of the other courses, plus training in all areas of the TAP system and the new TAP PAP system, so at the completion of the course, the participant has achieved both TAP and TAP PAP Certification."

"The TAP system has been hugely beneficial to patients in my practice," says Dr. Steve Bender, one of the Dental Institute of Sleep Medicine faculty members. "Dr. Thornton is a third generation dentist who has dedicated the last decade of practice to the treatment of sleep disordered breathing. He has over 52 US and foreign patents on oral appliances, CPAP masks, and combination oral appliance mask interface systems. The TAP is the market leader and most prescribed adjustable oral appliance for sleep apnea. More than 250,000 have been delivered worldwide."

"The TAP system is not only efficacious," says Dr. Paul McLornan, a prosthodontist in private practice and assistant professor at the University of Texas Health Sciences Center in San Antonio Dental School. "It is the only appliance shown to be not inferior to CPAP. Sleep disordered breathing contributes more to morbidity and mortality than patients realize. Most dentists are not aware that they can now easily develop the ability to help their patients and also offer therapeutic options to CPAP. All general dentists would benefit from higher awareness and many would benefit from adding oral appliance therapy for sleep disordered breathing to their practice services. Patterson Dental is to be commended for moving forward as an educational leader in this arena."

Here is the original post:

Airway Management Forms Dental Institute of Sleep Medicine

PHILADELPHIA Garret FitzGerald, MD, chair of the Department of Pharmacology and Director of the Institute for Translational Medicine & Therapeutics, Perelman School of Medicine at the University of Pennsylvania, is among the 44 newly elected Fellows and eight newly elected Foreign Members to the Royal Society.

"Science impacts on most aspects of modern life, improving our understanding of the world and playing an increasing role as we grapple with problems such as feeding a growing global population and keeping an aging population healthy. These scientists who have been elected to the Fellowship of the Royal Society are among the world's finest. They follow in the footsteps of luminaries such as Newton, Darwin and Einstein and I am delighted to welcome them into our ranks," noted Sir Paul Nurse, President of the Royal Society.

FitzGerald, also professor of Medicine and Pharmacology and the McNeil Professor in Translational Medicine and Therapeutics, takes an integrative approach to elucidating the mechanisms of drug action. He was the first to describe the dose-dependent suppression by aspirin of thromboxane and prostacyclin in humans and animal models. This body of research contributed substantially to the development of low-dose aspirin as a preventive approach to heart disease. His group was the first to predict and then explain mechanistically the cardiovascular hazard from NSAIDs. His team was also the first to discover a molecular clock in the cardiovascular system, which has contributed substantially to the understanding of the importance of peripheral clocks in the regulation of cardiovascular and metabolic function.

"I am deeply honored by this recognition of the efforts and accomplishments of those with whom I have been privileged to work," said FitzGerald.

The Royal Society is a self-governing fellowship of many of the world's most distinguished scientists drawn from all areas of science, engineering, and medicine. The Society's fundamental purpose, as it has been since its foundation in 1660, is to recognize, promote, and support excellence in science and to encourage the development and use of science for the benefit of humanity.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Read this article:

Perelman School of Medicine Professor Elected to the Royal Society

OKLAHOMA CITY, OK--(Marketwire -04/24/12)- Graymark Healthcare, Inc. (NASDAQ: GRMH - News), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), opened four new facilities for its comprehensive sleep medicine services in the second quarter of 2012.

These new sleep centers bring the aggregate number to 105 and allows Graymark to better serve patients within these markets. The locations of the new standalone Graymark sleep centers include:

Patients in the geographic regions these hospitals serve can now receive sleep medicine care in familiar surroundings, while Graymark Healthcare ensures comprehensive, state-of-the-art services. Together, the new centers will add 10 beds to the Dallas/Fort Worth and Atlanta markets.

Including today's new locations, Graymark now operates a total of 105 sleep locations nationwide, consisting of 19 standalone facilities, seven therapy facilities and 79 hospital or rural outreach locations. While the care environments may vary based on community need, Graymark ensures that the quality and comprehensiveness of the services provided remain at the highest standard.

"The opening of these four new sleep centers is directly due to the increased volume we are experiencing for our comprehensive model of diagnosing and treating patients afflicted by sleep apnea," said Stanton Nelson, CEO of Graymark Healthcare. "With the additional Atlanta locations, we were able to leverage our successful partnership with Emory-Adventist Hosipital -- our first entrance into the Georgia market -- to expand our market share in the region. The Mesquite, Texas location also represents our tenth location in the Dallas-Fort Worth region, making Graymark the market leader in terms of number of sleep studies conducted in the area."

In addition to treating all sleep disorders, including narcolepsy, insomnia, and restless leg syndrome, Graymark specializes in the treatment of sleep apnea, a sleep disorder characterized by abnormal pauses in breathing. Each pause or "apnea" can last from a few seconds to minutes, and can occur from five to more than 30 times per hour. OSA is the most common form of apnea and occurs when the soft tissue in the airway obstructs breathing. The proper diagnosis and treatment of OSA is critical due to the many significant associated health risks, including stroke and cardiac disease.

Graymark Healthcare's effective five step clinical approach to managing sleep disorders includes a convenient referral process, accurate and timely assessment, diagnosis, treatment and long-term follow-up to maximize patient compliance. All steps are managed by a board certified Sleep Medicine physician. To find out more or to locate a sleep center near you, visit http://www.graymarkhealthcare.com.

About Graymark HealthcareHeadquartered in Oklahoma City, Okla., Graymark Healthcare, Inc. (NASDAQ: GRMH - News) is the nation's second largest provider of sleep management solutions. In addition to diagnosing and treating over 80 sleep disorders, the company specializes in comprehensive care for Obstructive Sleep Apnea (OSA). Graymark offers its services through 105 sleep laboratories primarily in the Midwest, including standalone or IDTF facilities, therapy facilities, rural outreach hospital sites and urban hospital management agreements. For more information, visit http://www.graymarkhealthcare.com.

Important Cautions Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on the Company's current expectations, forecasts and assumptions. Forward-looking statements involve risks and uncertainties that could cause actual outcomes and results to differ materially from the Company's expectations, forecasts and assumptions. These risks and uncertainties include risks and uncertainties not in the control of the Company, including, without limitation, the risk that the transaction does not close as planned or at all, the current economic climate and other risks and uncertainties, including those enumerated and described in the Company's filings with the Securities and Exchange Commission, which filings are available on the SEC's website at http://www.sec.gov. Unless otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Link:

Graymark Healthcare Opens Four New Facilities for Sleep Medicine Services

PHILADELPHIA Perelman School of Medicine researchers Thomas Curran, PhD, professor of Pathology and Laboratory Medicine, and Gary A. Koretzky, MD, PhD, vice chair for research and chief scientific officer, Department of Medicine, and are among the 220 elected to the 2012 class of members of the American Academy of Arts and Sciences.

One of the nation's most prestigious honorary societies, the Academy is also a leading center for independent policy research. The current membership includes some of the world's most accomplished leaders from academia, business, public affairs, the humanities and the arts.

Gary A. Koretzky is also a Francis C. Wood professor in the Department of Medicine. Through investigations of the regulation of blood cell formation and movement, Koretzky has made inroads into understanding the complexities of immune system function.

Thomas Curran is also an investigator at the Abramson Family Cancer Research Institute and deputy scientific director at the Children's Hospital of Philadelphia. Curran's studies of the molecular basis of brain cell growth have informed new strategies to treat pediatric brain tumors. He is an elected member of the Institute of Medicine and of the Royal Society.

The other Penn winners admitted to this years' class are Robert M. Seyfarth, professor of psychology, George J. Mailath, Walter H. Annenberg Professor in the social sciences and professor of economics, and Michael Kearns, professor and National Center Chair in Resource Management and Technology, Computer and Information Science Department.

An alphabetical list of the 220 new members is at http://www.amacad.org/news/alphalist2012.pdf.

The new class will be inducted at a ceremony on Oct. 6, at the Academy's headquarters in Cambridge, Mass. For full release on all Penn winners, visit http://www.upenn.edu/pennnews/news/five-penn-professors-elected-american-academy-arts-and-sciences.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

Read more:

Perelman School of Medicine Researchers Elected to American Academy of Arts and Sciences

TIJUANA, Mexico, April 23, 2012 (GLOBE NEWSWIRE) -- Regenerative Medicine Institute, Mexico (RMI) will be among top scientists and physicians presenting cutting edge data at the International Society of Stem Cell Research (ISSCR). The ISSCR's annual meeting has become the world's premier stem cell research event. The meeting serves as the largest forum for stem cell and regenerative medicine professionals from around the world. The ISSCR 10th Annual Meeting will be held June 13 - 16, 2012 at the Pacifico Yokohama in Yokohama, Japan.

A summary of data on the use of adult stem cells from adipose tissue to treat heart failure and COPD will be presented by Kristin Comella, Chief Scientific Officer of Bioheart Inc. Bioheart is focused on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. RMI is currently running Phase I/II trials at the Hospital Angeles in collaboration with Bioheart and the Ageless Regenerative Institute.

Dr. Javier Lopez, President and CEO of RMI and a member of ISSCR said that "We are proud to share our initial results with the scientific community at such a prestigious event."

For more information on RMI, visit http://www.regenerativemedicine.mx

Go here to see the original:

Regenerative Medicine Institute, Mexico Presents Summary of Clinical Data at the International Society of Stem Cell ...

NEW YORK, April 24, 2012 /PRNewswire/ -- The third Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium held on July 20-22, 2012 at the Conrad New York, promises to be the most ground-breaking conference to date, featuring the latest advancements in aesthetic surgery, cosmetic medicine and anti-aging therapies. The world-class multi-specialty faculty includes plastic surgeons, facial plastic surgeons, dermatologists and oculoplastic surgeons from across the U.S., Canada and Europe.

Attendees of this year's Next Generation Symposium can expect to learn about the most important future developments in medical aesthetics. Course Chairman New York Plastic Surgeon Z. Paul Lorenc, M.D., F.A.C.S. states, "With the economy turning around, we are encouraged by the interest from investors and research in our field. There are many outstanding and significant innovations emerging that we will discuss at the Symposium, most notably in the areas of body shaping technologies, autologous fat, stem cells and plasma rich platelets, anti-aging topicals and injectables."

According to Washington D.C. Dermatologist Cheryl Burgess, M.D., "The comprehensive live injection workshop will feature a superb faculty of experts, including Drs. Rebecca Fitzgerald, Heidi Waldorf, Steven Fagien, Sabine Zenker, Brian Kinney, Haideh Hirmand, and Miles Graivier, who will share their collective experience with dermal fillers, facial volumizing techniques, and neurotoxins. It will be an unbiased, balanced and informative format for aesthetic practitioners to perfect their skills."

New for 2012, there will be special workshops covering a range of hot topics and emerging technologies including new laser and energy based devices, advanced skin peels, 3D imaging, practice marketing and branding, treating skin of color, and Platelet-rich Fibrin Matrix. This year's roster of sponsors and exhibitors shall include ZO Skin Health, Aesthetic Factors, Ellman International, Merz Aesthetics, Andrew Technologies, Sciton, Nordson Micromedics, Medicis, SkinMedica, Valeant, and Ethicon/Mentor. Open to physicians as well as nurses, aestheticians and office staff, the interactive Next Generation meeting offers excellent opportunities to network with colleagues and exhibitors, and learn invaluable pearls and techniques.

About Aesthetic Plastic Surgery & Anti-Aging Medicine: The Next Generation - An interdisciplinary approach to disseminating, teaching and promoting the most advanced information and developments in the fields of aesthetic plastic surgery and anti-aging medicine.

For information about sponsorship opportunities and early bird registration, visit http://www.nextgenmtg.org

Like us on http://www.facebook.com/apssny and http://www.twitter.com/nextgenmtgfor daily updates and news

More here:

Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium Features Comprehensive Program and ...

Traditional Chinese medicine is enjoying increasing popularity all over the world. But two recently published studies show that the treatments can be harmful. The papers focus attention on the fact that not all of the ingredients in TCM treatments are listed, or even legal, and that some can cause cancer.

Critics have long warned that some mixtures can also contain naturally occurring toxins; contaminants such as heavy metals; added substances such as steroids, which can make them appear more effective; and traces of animals that are endangered and trade-restricted.

Now, researchers in Australia have investigated the issue using modern sequencing technology. The team analyzed 15 TCM samples seized by Australian officials.

We took these traditional preparations, smashed them to pieces and extracted the DNA from the powder, explained molecular geneticist Michael Bunce.

Some products contained material from animals classified as vulnerable or critically endangered, such as the Asiatic black bear and the Saiga antelope, just as the producers of the products claimed. But often, the medicine also harbored ingredients not mentioned on the packaging, the team reported online in PLoS Genetics.

In the herbal preparations that they tested, Bunce and his colleagues found members of 68 plant families, among them plants of the genera Ephedra and Asarum. Both can contain toxic substances such as aristolochic acid, banned in many countries because it causes kidney disease and upper urinary tract cancer, or UUC. Although detecting DNA from a certain species does not mean that a toxin produced by that plant is present, chemical analysis of one of the four samples containing Asarum did turn up aristolochic acid.

The threat posed by aristolochic acid is also highlighted in a paper published this month in the Proceedings of the National Academy of Sciences.

For this paper, researchers focused on Taiwan, which has the highest rate of UUC in the world. A previous analysis had shown that roughly one-third of the Taiwanese population consumed herbs likely to contain aristolochic acid.

The scientists sequenced the tumors of 151 patients with UUC. Among those with mutations in a tumor-suppressor gene that make people more vulnerable to cancer, 84 percent showed indications of exposure to aristolochic acid. The study provides compelling evidence that aristolochic acid is a primary cause of UUC in Taiwan, the authors argue.

Kai Kupferschmidt of ScienceNOW, the daily online news service of the journal Science

See the original post here:

Samples of traditional Chinese medicine are found to contain harmful ingredients